iPS Academia Japan, Inc.

Company Profile

https://ips-cell.net/e/

Contributing to the health and welfare of humanity by translating
iPS cell-related innovations into societal benefits.

iPS Academia Japan, Inc.

Contributing to the health and welfare of humanity by translating iPS cell-related innovations into societal benefits.

In the nearly two decades since the discovery of induced pluripotent stem (iPS) cells, academic research in this field has advanced remarkably, yielding numerous breakthroughs. Additionally, the use of iPS cell technology in industry has advanced on multiple fronts.

Since its founding in 2008, our company has been guided by our mission of "disseminating outcomes of iPS cell research to the industrial and scientific communities and quickly and reliably contributing to human health and welfare." Over our 17-year history, we have established a proven track record in patent licensing by actively aligning academia and industry.

The use of iPS cell technology has advanced primarily in regenerative medicine, disease research, and new drug development. However, its applications are expanding into more advanced and diverse areas.

In this evolving landscape of iPS cell technology, our company is committed to building a future shaped by iPS cell technology through our licensing efforts covering a wide range of iPS cell-related patents, from core patents to improvement patents.

I hope you will join us in support of our mission and our vision for the future of iPS cell technology.

Hideo Saji
President & CEO
iPS Academia Japan, Inc.
September 2025

Company Profile

Name	iPS Academia Japan, Inc.
Establised	June 25, 2008
Accredited TLO	Accredited as of January 22, 2016 as an official technology licensing organization under the “Law for Promoting University-Industry Technology Transfer”
Location	iPS Academia Japan, Inc. 207 International Science Innovation Building East Wing Kyoto University, 36-1 Yoshida-honmachi, Sakyo-ku, Kyoto, 606-8501 Japan
Capital	JPY 100 million
President & CEO	Hideo Saji Ph.D. Professor Emeritus, Kyoto University & Specially Appointed Professor, the Office of Institutional Advancement and Communications of Kyoto University (IAC) & Director, Kyoto Lifetech Innovation Support Center, Regional Industrial Revitalization Division of Advanced Science, Technology and Management Research Institute of KYOTO
Director	Hiroshi Seno MD., Ph.D. Professor, Graduate School of Medicine and Faculty of Medicine Kyoto University & Deputy Director-General, Office of Institutional Advancement and Communications of Kyoto University（IAC）
Director	Atsushi Onodera Head, Medical Applications Promoting Office of Center for iPS Cell Research and Application, Kyoto University & Director, TLO-Kyoto Co., Ltd.
Director	Hidehiko Hokoi Attorney, SACI LPC Kyoto Academia Law Office
Corporate Auditor	Sayaka Amemiya Attorney, Yodoyabashi & Yamagami LPC
Corporate Auditor	Takuko Sawada Executive Vice-President of Kyoto University for Industry-Government-Academia Collaboration, Vice Chairman of the Board, Shionogi & Co., Ltd.
Scientific Adviser	Shinya Yamanaka MD., Ph.D. Director Emeritus and Professor, Center for iPS Cell Research and Application, Kyoto University & Representative Director, CiRA Foundation
Business description	● Technology transfer involving the licensing of patented inventions related to iPS cells and stem cells ● Support for patenting iPS cell-related research outcomes from academia ● Insights into the current iPS cell patent landscape

Form of investment



Company History

2008	iPS Academia Japan established in Kyoto / The world's first iPS cell-related patent granted in Japan
2009	First license agreement concluded
2010	First international license agreement concluded
2011	Patents assigned by iPierian to Kyoto University
2012	The Nobel Prize in Physiology or Medicine awarded to Professor Yamanaka
2013	More than 10 academic institutions as licensors, 300+ licensable patents
2014	iPS Academia Japan business reorganization
2015	Relocation to the Kyoto University campus
2016	Accredited as a technology licensing organization
2017	Surpassed 500 licensable patents
2018	10th anniversary / iPS Academia Japan Grant established
2019	Surpassed 200 licensees
2020	Became a subsidiary of Kyoto University
2024	Surpassed 300 licensees

Mission

Our mission is to contribute to the health and welfare of humanity by translating iPS cell-related innovations into societal benefits.



iPS Academia Japan manages intellectual properties derived from iPS cell research through licensing in accordance with two key guidelines established by the Council for Science and Technology Policy—namely, the "Guidelines for Research Licenses for Intellectual Property Rights Stemming from Government-Funded R&D at Universities, etc." (May 23, 2006) and the "Guidelines for Facilitating the Use of Research Tool Patents in the Life Sciences (March 1, 2007)." In this way, we make the intellectual properties broadly available to the industrial and scientific communities under the policies of iPS Academia Japan.

1 Not-for-profit institutions may use intellectual properties for non-commercial research or educational purposes on a royalty-free basis without entering into a license agreement. However, not-for-profit institutions are not permitted to provide iPS cells—including differentiated cells derived from iPS cells—to for-profit organizations without the prior consent of iPS Academia Japan, Inc.

2 Licenses are, in principle, granted on a non-exclusive basis to for-profit entities at fair and reasonable royalty rates. Under specific conditions, however, an exclusive license agreement may be considered for intellectual properties related to iPS cell technologies, **excluding** the core platform technologies.

Licensing Scheme

Since its founding, iPS Academia Japan has managed a patent portfolio related to iPS cell technologies. We grant patent licenses to companies and research institutions developing medical technologies and drugs that make use of these innovations.



Early practical applications of iPS cell-related technologies are strongly expected in therapeutic fields, extending beyond their research value. At the same time, it is essential that innovations stemming from iPS cell research successfully reach society.

Fields for the commercialization of iPS cell-related technologies

Practical applications of iPS cell-related technologies are expanding into advanced and diverse areas, including drug discovery and development. Innovative business models are also being built around iPS cells.

Major Promising Areas for Commercialization of iPS Cells

Drug Discovery
applications such as pathogenesis and screening

Regenerative Medicine
applications such as transplantation and cell therapy

Cell Business
applications such as sales of iPS cells, iPS cell reprogramming kits, and culture media

Diversification of iPS Cell-Related Industries

The iPS cell-related market is diversifying. In addition to traditional players such as biotech and pharmaceutical companies, various companies from other industries, such as precision instruments, are aiming to put iPS cell-related technologies into practical use.



As of March 2025, iPS Academia Japan holds patent license agreements with 309 entities: 126 domestic and 183 international, encompassing both for-profit and not-for-profit organizations across a broad range of sectors.

Number of Our Licensees



Ratio by Purpose



Ratio by Industry

The successful negotiation of license agreements with various companies for research and development, and the commercialization of iPS cells demonstrates the continued growth and expansion of this field.



Our patent portfolio consists of the iPS cell-related patents and patent applications licensed from various academic institutions, including Kyoto University, as well as other universities and research institutions. As of August 2025, more than 800 patents and patent applications are licensed to and held by our company, covering approximately 200 patent families.



Licensors of our Patent Portfolio

A wide range of domestic and international institutions have licensed patents and patent applications to iPS Academia Japan, we then sublicense these rights to other companies.

- Kyoto University
- Gifu University
- Osaka University
- The National Institute of Advanced Industrial Science and Technology
- Nagoya City University
- Kobe University
- Accelerate Technologies Pte Ltd.
- Tokyo Women's Medical University
- Okayama University
- Tokyo University of Pharmacy and Life Sciences
- RIKEN, Institute of Physical and Chemical Research
- Japan Biological Informatics Consortium
- Nagasaki University
- The National Institute for Quantum Science and Technology
- University of Tsukuba
- Other institutions

[As of August 2025]

Ratio by Technology

As of August 2025, while reprogramming technologies initially dominated our patent portfolio upon our founding, the share of other technologies—such as differentiation and drug discovery—has grown significantly in recent years.



Our Patent License Programs

Our patent license programs are categorized into three according to business purpose and usage. Please select the contract category that best matches your project.



Financial conditions depend on licensed territories, patents, and other factors. Please contact us for more details.

*1 Please submit an inquiry if you are unsure whether a product is licensed or a company is our licensee.
*2 This reflects the minimum licensing scope, covering only a single country and limited to the following basic patents: AJ001, AJ002, AJ005, AJ006, AJ018, and AJ066.
*3 Entity sizes are determined based on our internal criteria.



Case 1: A testing equipment manufacturer plans to obtain iPS cells from a domestic not-for-profit organization for internal research and development of its automated iPS cell culture system. This case requires “Contract Type 1”.

→ Contract Type 1

Case 2: A pharmaceutical manufacturer plans to use iPS cells established via its own proprietary protocols for internal research and development of differentiation methods for specific cell types, tissues, and organs. This case requires “Contract Type 2”.

→ Contract Type 2

Case 3: A pharmaceutical manufacturer plans to differentiate iPS cells that were either obtained from a not-for-profit organization or purchased from our for-profit licensee into target cell types using its in-house protocols for internal research and development including drug discovery screening. This case requires “Contract Type 3”.

→ Contract Type 3

Case 4: A pharmaceutical manufacturer plans to differentiate iPS cells established via its own proprietary protocols into target cell types also using its in-house protocols for internal research and development including drug discovery screening. This case requires “Contract Type 4”.

→ Contract Type 4

Case 5: A reagent manufacturer plans to manufacture and market research use only tools such as iPS cell-derived differentiated cells or iPS cell reprogramming kits using its in-house protocols. This case requires a “Manufacture, Sales, and Service License”.

→ Manufacture, Sales, and Service License

Case 6: A pharmaceutical manufacturer plans to advance human iPS cell-based regenerative medicine products through clinical development with the goal of future commercialization. This case requires a “Therapeutics Use License”.

→ Therapeutics Use License

Case 7: A reagent manufacturer plans to obtain iPS cells from a distributer properly licensed by iPS Academia Japan for internal research and development of its automated iPS cell culture system. No contract agreement with iPS Academia Japan is necessary in this case.

→ No contract required.

Standard Financial Terms

The figure shows the financial terms for each type of differentiated cell when the following basic patents: AJ001, AJ002, AJ005, AJ006, AJ018, and AJ066, are licensed non-exclusively on a worldwide basis.
For more information, please contact the license division directly.

Fees and Royalties	SSE *1	Non-SSE
Upfront fee	US$13K	US$60K
Annual maintenance fee [until NDA approval]	US$12K	US$25K
Milestone payments on first IND applications in each of 3 areas *2	US$41K [in total of 3 areas]	US$130K [in total of 3 areas]
Milestone payments on first NDA applications in each of 3 areas *2	US$250K [in total of 3 areas]	US$295K [in total of 3 areas]
Milestone payment on achievement of sales total US$100M	US$400K	
Milestone payment on achievement of sales total US$500M	US$700K	
Running royalties	1.5% of sales of final products	
Annual minimum royalties [after NDA approval]	US$20K	US$25K

*1 A Small and Start-up Entity (SSE) is an entity that was founded no later than 10 years ago, employs 50 or fewer people, and has received no more than US$20 million in total investment.
*2 The three areas are North America, Europe, and the rest of the world.



iPS Academia Japan, Inc.

207 International Science Innovation Building East Wing Kyoto University
36-1 Yoshida-honmachi, Sakyo-ku, Kyoto, 606-8501 Japan

TEL: 075-754-0625 / FAX: 075-761-3577
E-mail: license@ips-ac.co.jp

From Kyoto Station on the Japan Railways(JR)

From major train stations	City bus route No. (bus stop location)	Ride from ... to	Travel time
Japan Railways (JR) Kyoto Station	No. 206 (D2 bus stop) *Bound for Kitaoji Bus Terminal via Kiyomizu-dera Temple	Kyoto Station - Kyodai Seimon-mae	about 40 min.
	No. 7 (A2 bus stop) *Bound for Ginkakuji Temple	Kyoto Station - Kyodai Nogakubu-mae	about 40 min.

▸iPS Academia Japan is a 30-minute taxi ride from Kyoto Station.

From Demachiyanagi Station on the Keihan Railway Oto Line

From major train stations	City bus route No. (bus stop location)	Ride from ... to	Travel time
Keihan Oto Line Demachiyanagi Station	No. 201 *Bound for Gion via Hyakumanben	Demachiyanagi Station Kyodai Seimon-mae	about 10 min.
	No.7 (A2 bus stop) *Bound for Ginkakuji Temple	Demachiyanagi Station- Kyodai Nogakubu-mae	about 10 min.

▸iPS Academia Japan is a 20-minute walk from Demachiyanagi Station.